Erasca receives FDA Fast Track Designation for naporafenib

Erasca announced that the United States Food and Drug Administration has granted Fast Track Designation to naporafenib in combination with trametinib for the treatment of adult patients with unresectable or metastatic melanoma who have progressed on, or are intolerant to, an anti-programmed death-1-based regimen, and whose tumors contain an NRAS mutation. Naporafenib is an orally available, Phase 3-ready pan-RAF inhibitor with a potential first-in-class and best-in-class profile in NRASm melanoma and other RAS/MAPK pathway-altered solid tumors.